<html>
<head>
<title>Section 318:51-d Requirements for Outsourcing Facilities.</title>
<!-- Hide metadata
<titlename>TITLE XXX OCCUPATIONS AND PROFESSIONS</titlename>
<chapter>CHAPTER 318 PHARMACISTS AND PHARMACIES</chapter>
<sectiontitle>Section 318:51-d Requirements for Outsourcing Facilities.</sectiontitle>
-->
<meta name="titlename" content="TITLE XXX OCCUPATIONS AND PROFESSIONS">
<meta name="chapter" content="CHAPTER 318 PHARMACISTS AND PHARMACIES">
<meta name="sectiontitle" content="Section 318:51-d Requirements for Outsourcing Facilities.">
<meta name="sourcenote" content="Source.  2015, 180:3, eff. July 1, 2015.">
<meta name="codesect" content="<br>&nbsp&nbsp&nbspI. Outsourcing facilities shall maintain a human drug compounding outsourcing facility registration from the United States Food and Drug Administration (FDA) and shall comply with applicable Current Good Manufacturing Practices (CGMP) requirements as defined in the Final Guidance for Industry-Human Drug Compounding Outsourcing Facilities under Section 503B of the Food, Drug, and Cosmetic Act, when compounding or manufacturing drug products for sale in New Hampshire.<br>&nbsp&nbsp&nbspII. Facilities are subject to inspection by the FDA on a risk-based schedule.<br>&nbsp&nbsp&nbspIII. Outsourcing facilities shall be in compliance with applicable United States Drug Enforcement Administration (DEA) regulations.<br>&nbsp&nbsp&nbspIV. As part of the New Hampshire outsourcing facility license application process, the pharmacist-in-charge shall certify to the board that the facility is in full compliance with all applicable FDA and DEA regulations and guidelines, and state law and rules.<br>&nbsp&nbsp&nbspV. Outsourcing facilities shall be required to test all finished drug products compounded from bulk active pharmaceutical ingredients (API) to determine whether they meet final product specifications before their release for distribution.  No products shall be released for use until this testing is conducted and the results confirm that the finished drug product meets specifications.  Copies of the test results shall be included with each batch sent to New Hampshire customers and available for inspection by the pharmacy board.<br>&nbsp&nbsp&nbspVI. Outsourcing facilities compounding drug products from sterile, commercially available raw materials shall confirm sterility through process control validated by testing of at least 20 percent of the lots of each product shipped into New Hampshire.  Results of these tests shall be provided to New Hampshire customers in receipt of the compounded preparations and available for inspection by the pharmacy board.">
</head>
<body>
<center><h1>TITLE XXX<br>OCCUPATIONS AND PROFESSIONS</h1></center>
<center><h2>CHAPTER 318<br>PHARMACISTS AND PHARMACIES</h2></center>
<center><h2>Possession and Sale of Drugs and Devices for Administration of Drugs</h2></center>
<center><h3>Section 318:51-d</h3></center>
<br><center>[RSA 318:51-d repealed by 2015, 180:4, effective as provided by 2015, 180:5.]</center>
&nbsp;&nbsp;&nbsp;<b> 318:51-d Requirements for Outsourcing Facilities. &#150;</b>
<codesect>
<br>
&nbsp&nbsp&nbsp
I. Outsourcing facilities shall maintain a human drug compounding outsourcing facility registration from the United States Food and Drug Administration (FDA) and shall comply with applicable Current Good Manufacturing Practices (CGMP) requirements as defined in the Final Guidance for Industry-Human Drug Compounding Outsourcing Facilities under Section 503B of the Food, Drug, and Cosmetic Act, when compounding or manufacturing drug products for sale in New Hampshire.
<br>
&nbsp&nbsp&nbsp
II. Facilities are subject to inspection by the FDA on a risk-based schedule.
<br>
&nbsp&nbsp&nbsp
III. Outsourcing facilities shall be in compliance with applicable United States Drug Enforcement Administration (DEA) regulations.
<br>
&nbsp&nbsp&nbsp
IV. As part of the New Hampshire outsourcing facility license application process, the pharmacist-in-charge shall certify to the board that the facility is in full compliance with all applicable FDA and DEA regulations and guidelines, and state law and rules.
<br>
&nbsp&nbsp&nbsp
V. Outsourcing facilities shall be required to test all finished drug products compounded from bulk active pharmaceutical ingredients (API) to determine whether they meet final product specifications before their release for distribution.  No products shall be released for use until this testing is conducted and the results confirm that the finished drug product meets specifications.  Copies of the test results shall be included with each batch sent to New Hampshire customers and available for inspection by the pharmacy board.
<br>
&nbsp&nbsp&nbsp
VI. Outsourcing facilities compounding drug products from sterile, commercially available raw materials shall confirm sterility through process control validated by testing of at least 20 percent of the lots of each product shipped into New Hampshire.  Results of these tests shall be provided to New Hampshire customers in receipt of the compounded preparations and available for inspection by the pharmacy board.
</codesect>
<sourcenote>
<p><b>Source.</b>  2015, 180:3, eff. July 1, 2015.</p>
</sourcenote>
</body>
</html>
